Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization
International Journal of Environmental Research and Public Health
; 18(1):102, 2021.
Article
in English
| ScienceDirect | ID: covidwho-984768
ABSTRACT
Introduction:
The Coronavirus disease 2019 (COVID-19) outbreak is a whole Earth health emergency related to a highly pathogenic human coronavirus responsible for severe acute respiratory syndrome (SARS-CoV-2). Despite the fact that the majority of infected patients were managed in outpatient settings, little is known about the clinical characteristics of COVID-19 patients not requiring hospitalization. The aim of our study was to describe the clinical comorbidity and the pharmacological therapies of COVID-19 patients managed in outpatient settings. Materials andMethods:
We performed an observational, retrospective analysis of laboratory-confirmed COVID-19 patients managed in outpatient settings in Naples, Italy between 9 March and 1 May 2020. Data were sourced from the prospectively maintained Health Search (HS)/Thales database, shared by 128 primary care physicians (PCPs) in Naples, Italy. The clinical features and pharmacological therapies of COVID-19 patients not requiring hospitalization and managed in outpatient settings have been described.Results:
A total of 351 laboratory-confirmed COVID-19 patients (mean age 54 ±17 years;193 males) with outpatient management were evaluated. Hypertension was the most prevalent comorbidity (35%). The distribution of cardiovascular comorbidities showed no gender-related differences. A total of 201 patients (57.3%) were treated with at least one experimental drug for COVID-19. Azithromycin, alone (42.78%) or in combination (27.44%), was the most widely used experimental anti-COVID drug in outpatient settings. Low Molecular Weight Heparin and Cortisone were prescribed in 24.87% and 19.4% of the study population, respectively. At multivariate regression model, diabetes (risk ratio (RR) 3.74;95% CI 1.05 to 13.34;p = 0.04) and hypertension (RR 1.69;95% CI 1.05 to 2.7;p = 0.03) were significantly associated with the experimental anti-COVID drug administration. Moreover, only diabetes (RR 2.43;95% CI 1.01 to 5.8;p = 0.03) was significantly associated with heparin administration.Conclusions:
Our data show a high prevalence of hypertension, more likely treated with renin–angiotensin–aldosterone system (RASS) inhibitors, among COVID-19 patients not requiring hospitalization. Experimental COVID-19 therapies have been prescribed to COVID-19 patients considered at risk for increased venous thromboembolism based on concomitant comorbidities, in particular diabetes and hypertension.
Search on Google
Collection:
Databases of international organizations
Database:
ScienceDirect
Language:
English
Journal:
International Journal of Environmental Research and Public Health
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS